Skip to main content

Clonazepam-induced lichenoid drug eruption: a case report



Lichenoid drug eruption is rare and can mimic idiopathic lichen planus and other dermatoses. Clonazepam, a commonly used drug for the treatment of anxiety-related disorders and seizures, is known to be an unlikely cause of cutaneous adverse effects. Only one case report of LDE due to clonazepam has been reported.

Case presentation

A 81-year-old male patient with Alzheimer’s disease developed a lichenoid eruption after taking clonazepam. He developed a violaceous scaly patch on his lower extremities, from both buttocks to the feet. The cutaneous eruption resolved 2 months after cessation of clonazepam and with initiation of corticosteroid therapy.


A skin eruption that develops after clonazepam administration can be a lichenoid drug eruption, which is less likely to resolve spontaneously and requires discontinuation of clonazepam administration.

Peer Review reports


Drug eruption is the most common adverse drug reaction. The list of conditions that can be triggered by medications includes nearly all dermatological diseases, ranging from mild and moderate such as pruritus and lichenoid eruptions to severe ones like Stevens-Johnson syndrome [1]. Lichenoid drug eruption (LDE) is a rare type of drug eruption that can resemble idiopathic lichen planus (LP) clinically and histopathologically. LDE is induced by various drugs, such as gold salts, antimalarial drugs, β-blockers, angiotensin-converting-enzyme inhibitors [2]. Clonazepam is one of the most commonly used drugs for treating anxiety-related disorders and seizures. Common side effects such as drowsiness and sedation are well known and can be appropriately considered by clinicians. However, rare hypersensitivity reactions and cutaneous adverse effects are difficult to consider in most clinical situations and only one case report of LDE due to clonazepam has been reported [3, 4].

In the current case report, we present an 81-year-old Alzheimer’s disease (AD) patient with LDE induced by clonazepam. We aim to increase the clinicians’ insights into a rare drug eruption, and importance of early identification of the offending drug which may reduce unnecessary discomfort in patients due to delayed diagnosis.

Case presentation

An 81-year-old man with 3 to 4 years of slowly progressive memory impairment visited the clinic for evaluation. The patient reported difficulty in recalling where he placed objects, and difficulty in understanding news programs. Except for memory impairment, other cognitive domains such as language, orientation, judgment, personality, and behavior were intact. In neuropsychological tests, he showed poor performance in word list recall and recognition, below − 2 standard deviation, while the scores in other cognitive domains were within the normal limit. He was receiving long-term treatment with enalapril for hypertension and had no other diseases or medications. He had a history of regular alcohol consumption (2 standard drinks per day) for 56 years, and had quit smoking 30 years ago. Detailed physical and neurological examinations did not reveal any abnormality. His blood tests were normal except for mild hypercholesterolemia. Magnetic resonance imaging (MRI) showed diffuse brain atrophy and bilateral hippocampal atrophy. Medial temporal lobe scores were 1/2 each on the left and right according to the Skeltens scale [5]. According to the Fazekas scale, the rating of white matter hyperintensities was 2 on the periventricular white matter and 1 on the deep white matter [6]. A positron emission tomography (PET) scan showed diffuse hypometabolism in the left frontoparietal cortices. Based on clinical findings and imaging biomarkers, he was diagnosed with mild cognitive impairment due to AD according to the diagnostic criteria proposed by the National Institute on Aging-Alzheimer’s Association (NIA-AA) [7]. Donepezil was started at 2.5 mg/day, escalating to 10 mg/day over several months. At 18 months, he had difficulty with nighttime sleep, and clonazepam 0.25 mg/day was started.

Three weeks after starting clonazepam, the patient visited the dermatology outpatient clinic in our hospital with itchy eruptions on the lower extremities. His skin lesions had already improved to some extent by self-applying steroid ointment 3 days before. Because he had suffered from unspecified dermatitis for a long time and there was no history of allergy or drug reaction, a drug eruption was not suspected at the time. Since the lesions started to resolve, he was decided to follow up without special treatment, and only a p.r.n. topical steroid was prescribed. Since then, the lesions did not fully remit but rather spread, and the patient re-visited after 4 months. Physical examination revealed a violaceous scaly patch on the lower extremities, from both buttocks to feet (Fig. 1a,b). For further evaluation, laboratory tests and tissue biopsy were performed. His eosinophil count was slightly elevated to 7.1%, while other laboratory values were within the normal range. The histopathological findings of the eruptions on the left lower leg showed a lichenoid dermatitis pattern (Fig. 2). Based on clinical and histopathological findings, clonazepam-induced LDE was most strongly suspected. Clonazepam was discontinued, and zolpidem was prescribed for sleep control. Additionally, he was treated with a week of oral steroids and tacrolimus 0.1% ointment.

Fig. 1

Violaceous scaly patch on the left foot (a) and both lower legs (b)

Fig. 2

Histopathological findings show lichenoid dermatitis pattern with superficial perivascular lymphocyte infiltration and focal basal vacuolization (H&E stain, × 100, × 400)

Although new lesions appeared on the upper extremities, most of the existing lesions gradually improved 1 month after clonazepam was discontinued. All eruptions disappeared over the next month and there was no recurrence after that. Sleep was well controlled by intermittent administration of zolpidem, and no more benzodiazepine was prescribed, including clonazepam. Memantine was added due to progressive cognitive decline, but no adverse reaction occurred.

Discussion and conclusions

In the current case, LDE developed in patients with preexisting dermatitis after taking clonazepam, and it was improved over several months after cessation of the drug. Clonazepam is commonly prescribed for treating a range of disorders for which it had not originally been approved, including sleep-related disorders, withdrawal from other benzodiazepines, and pain management [8]. Clonazepam has been rarely associated with cutaneous adverse reactions, and only a few cases, such as erythema multiforme, pseudo-mycosis fungoides, localized exfoliating eruptions, alopecia, bullous dermatosis, and eczematous drug eruption have been reported [9,10,11,12,13,14]. To the best of our knowledge, only two case reports of LDE due to clonazepam has been reported [4, 15].

Cutaneous adverse effects of clonazepam are idiosyncratic and have been reported in a few patients taking various doses ranging from 0.5 to 2 mg/day [9,10,11,12,13,14]. Only one patient developed an LDE with clonazepam; however, this patient’s dosage was not stated [4]. Our patient with clonazepam-induced lichenoid eruption was treated at 0.25 mg/day. The incidence of LDE was known to be dependent on the causative drug rather than the dose [2]. LDE is less likely to resolve spontaneously and may require cessation of the offending agent in addition to corticosteroid therapy [16]. Therefore, in the case of clonazepam-induced LDE, it may be reasonable to discontinue the drug rather than to consider dose reduction.

LDE seems to have a long latent period of 4 weeks to 3 years, while the latent period of most drug eruptions is about 1 or 2 weeks, or up to 1 month. The identification of the offending drug can be complicated by such variability in the latent period between intake of a drug and appearance of the eruption. The latent period may vary depending on the offending drug, the dosage of the drug, and the patient’s individual reaction to the drug. The length of the resolution also depends on the offending drug, and it may be up to 5 months [2]. In our case, it was difficult to determine the onset of LDE due to comorbid dermatitis, but the latent period may be estimated from about 3 weeks to 4 months. After clonazepam was discontinued, it took 2 months for the lesions to disappear, which was in line with the typical course of LDE.

In the current case, the patient has also taken enalapril and lichen planus-like eruptions induced by enalapril have been reported a few times in the literature [17,18,19]. The contribution of clonazepam and enalapril in our patients development of LDE was evaluated by using the Naranjo Adverse Drug Reaction (ADR) Probability Scale [20], which revealed the probable influence of clonazepam and the possible influence of enalapril in LDE development. Therefore, it may be presumed that clonazepm had a higher impact on LDE development than enalapril. In addition, previous literatures reported that lichen planus-like eruption due to enalapril appeared between 6 weeks and 6 months [17,18,19]. In our case, enalapril had been taken for 11 years, which was less likely to cause LDE because it is much longer than the longest reported latent period.

Cytochrome P-450 including CYP3A, may play an important role in clonazepam metabolism. There is no evidence that clonazepam induces its own metabolism or that of other drugs in humans [3]. Enalapril is prodrugs metabolized in the liver, and some animal studies provide information suggesting that prodrugs seem to undergo CYP3A4-dependent biotransformation. However, the angiotensin-converting enzyme inhibitors including enalapril are not involved in significant cytochrome P450–mediated interactions with other drugs [21]. Therefore, a clinically significant interaction was not strongly expected.

Similar to other forms of drug eruptions, withdrawal of the suspected drug followed by the disappearance of the lichenoid eruption may confirm the diagnosis of LDE [2]. In this case, the course of rash disappearance after cessation of clonazepam was clear, so it was possible to diagnose clonazepam-induced LDE. As in the previously reported case, the most confirmative way to determine the causative drug may be to ascertain the disappearance of the eruption after cessation of the suspected drug and to reproduce the eruption by re-administering the drug [4]. However, re-exposure of the offending drug for diagnosis only may be dangerous and, therefore, not recommended. Topical provocation tests, which were not performed in our case, are safer, while it is known to have a higher false-negative rate [2, 22].

In conclusion, although it is not frequent, clonazepam may cause drug eruptions, such as LDE. Therefore, if eruptions appear after newly prescribed clonazepam, a thorough history taking and investigations should be performed, and if necessary, changing the drug and referencing to a dermatologist are advised.

Availability of data and materials

Not applicable.



Lichenoid drug eruption


Lichen planus


Alzheimer’s disease


Magnetic resonance imaging


Positron emission tomography


National Institute on Aging-Alzheimer’s Association


  1. 1.

    Hoetzenecker W, Nageli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38(1):75–86.

    CAS  Article  Google Scholar 

  2. 2.

    Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 1993;29(2 Pt 1):249–55.

    CAS  Article  Google Scholar 

  3. 3.

    US FDA. Klonopin tablets (clonazepam) Klonopin wafers (clonazepam orally disintegrating tablets) 2010. Available from:,020813s006s007lbl.pdf.

    Google Scholar 

  4. 4.

    Muramatsu K, Ujiie H, Natsuga K, Nishie W, Shimizu H. Lichenoid drug eruption caused by clonazepam. J Eur Acad Dermatol Venereol. 2017;31(2):e117–e8.

    CAS  Article  Google Scholar 

  5. 5.

    Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242(9):557–60.

    CAS  Article  Google Scholar 

  6. 6.

    Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–6.

    CAS  Article  Google Scholar 

  7. 7.

    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270–9.

    Article  Google Scholar 

  8. 8.

    Dokkedal-Silva V, Berro LF, Galduroz JCF, Tufik S, Andersen ML. Clonazepam: indications, side effects, and potential for nonmedical use. Harv Rev Psychiatry. 2019;27(5):279–89.

    Article  Google Scholar 

  9. 9.

    Amichai B, Grunwald MH. Erythema multiforme due to clonazepam - supportive evidence from the macrophage migration inhibition factor test. Clin Exp Dermatol. 1998;23(5):206–7.

    CAS  Article  Google Scholar 

  10. 10.

    Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, et al. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996;34(2 Pt 1):304–6.

    CAS  Article  Google Scholar 

  11. 11.

    Munoli RN, Praharaj SK, Bhatt SM. Localized exfoliating rash with paresthesia possibly due to clonazepam. J Child Adolesc Psychopharmacol. 2012;22(4):320–1.

    CAS  Article  Google Scholar 

  12. 12.

    Virit O, Savas HA. Hair loss associated with clonazepam. Clin Neuropharmacol. 2009;32(1):56.

    Article  Google Scholar 

  13. 13.

    Lee MC, Su CP, Wang CH, Lan CC, Wu TW. Suspected clonazepam-induced bullous dermatosis in a patient with respiratory failure. J Clin Pharmacol. 2012;52(10):1607–9.

    CAS  Article  Google Scholar 

  14. 14.

    Yoshida A, Sugita K, Tani N, OY. Correlation between serum TARC levels and eczematous drug eruption following oral challenge test with clonazepam. Clin Exp Dermatol. 2020;45(8):1063-5.

  15. 15.

    Pourshahidi S, Samami M. Clonazepam-induced Oral Lichenoid reaction: a case report. New York State Dent J. 2020;86:24–7.

    Google Scholar 

  16. 16.

    Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced Lichenoid drug eruption: a case report and review of statin-associated cutaneous adverse events. Cureus. 2020;12(3):e7155.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Ruiz VR, Blasco MJ, Linares SJ, Serrano OS. Lichen planus-like eruption due to enalapril. J Eur Acad Dermatol Venereol. 2003;17(5):612–4.

    Article  Google Scholar 

  18. 18.

    Roten SV, Mainetti C, Donath R, Saurat JH. Enalapril-induced lichen planus-like eruption. J Am Acad Dermatol. 1995;32:293–5.

    CAS  Article  Google Scholar 

  19. 19.

    Kanswar A, Dhar S, Ghosh S. Photosensitive lichenoid eruption due to enalapril. Dermatology. 1995;187:80.

    Article  Google Scholar 

  20. 20.

    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.

    CAS  Article  Google Scholar 

  21. 21.

    Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405–12.

    CAS  Article  Google Scholar 

  22. 22.

    Agullo-Garcia A, Garces Sotillos M, Colas SC. Fixed drug eruption due to Lorazepam. J Investig Allergol Clin Immunol. 2018;28(3):185–6.

    CAS  Article  Google Scholar 

Download references


Not applicable.



Author information




KWK and JN were involved in the management and assessment of the patient. HWY wrote the first draft of the manuscript. JBB, JN and KWK participated in the revision of the draft manuscript. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Jong Bin Bae.

Ethics declarations

Ethics approval and consent to participate

We obtained ethical approval from the Institutional Review Board of the Seoul National University Bundang Hospital (IRB No. L-2020-598-3).

Consent for publication

A written consent from the patient was obtained for publication.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, H.W., Bae, J.B., Na, JI. et al. Clonazepam-induced lichenoid drug eruption: a case report. BMC Psychiatry 21, 125 (2021).

Download citation


  • Clonazepam
  • Cutaneous
  • Lichenoid
  • Drug eruption